Company Overview
Malaria Diagnostics in stealth- mode is developing a novel malaria diagnostics technology aiming to improve accuracy, reduce costs and provide broad availability.
The unstained (no reagents) malaria diagnostics technology requires minimal infrastructure and leverages AI for analysis.
The value proposition lies in a novel approach combining the medical performance of microscopy with the convenience and cost of Rapid Diagnostic Tests.
Market Overview
Driven by > 249m global malaria cases in 2022 (CAGR of 5.4% through 2027) with high prevalence in sub-Saharan Africa.
Available Diagnostics Tools use stained microscopy (gold-standard), Rapid Diagnostic Tests, and Molecular Diagnostic Tests, with ongoing efforts to develop more efficient and accessible tools.
Notable companies: Abbott Laboratories, BioMérieux, Cepheid among others are active in malaria diagnostics with stained solutions.
Our pipeline
Q4’24 – Development and field testing phase completed
Q3’25 – Performance and manufacturing readiness achieved
Q3’25 – Performance and manufacturing readiness achieved
Company Overview
PIUR developed a vendor agnostic add-on to any existing ultrasound device, enabling the generation of 3D tomographic ultrasound images through image reconstruction algorithms.
Decision support for HCPs in extracting diagnostic information from 3D images.
Decreasing operator dependency and opening the market for tele diagnostics and retrospective image analysis.
Market Overview
Ultrasound with a global existing installed base of > 500,000 devices (ultrasound as cost-efficient globally adapted and well-understood technology).
An inherent need from blue-chips to innovate their product offering with decision support software is a tailwind for players like PIUR Imaging. The GE HealthCare partnership for integration of PIUR’s software proves this claim.
Our pipeline
Q2’24 – Commercial kick-off for the GE HealthCare integrated product in the EU
Q4’24 – FDA approval for PIUR’s standalone product
Q2’25 – FDA approval for the GE HealthCare integrated product
Q3’25 – Commercial kick-off for the GE HealthCare integrated product in the US
Our strategy anticipates a high ramp up with the upcoming US sales and through this, GE´s appetite of acquiring PIUR to strategically outmaneuver competitors like Philips.
We anticipate a valuation increase of 4.0x, driven by potential M&A with strategic partners, offering earlier exit opportunities at lower multiples. The initial boost in valuation will stem from the commencement of commercial activities with strategic partners Curium Pharma and GE Healthcare in Europe. The FDA approval of tUS Infinity in Q3 2024 will prompt a further valuation increase, succeeded by the approval and U.S. launch of the GE-integrated tUS inside.
